Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Neil T. Formica
Observed names:
N. FORMICA,
Neil Formica
Institution:
Novavax (United States)
Observed institutions:
Australian National University,
University of Maryland, Baltimore,
Monash Medical Centre,
Department of Health and Human Services,
Novavax (United States),
CSL (Australia),
Seqirus (Australia)
show all 7
ORCID:
0000-0001-6696-3975
Observed ORCID:
0000-0001-6696-3975
OpenAlex ID:
A5017199045
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
2020
·
Cheryl Keech
, Gary Albert
, et al.
·
New England Journal of Medicine
·
1,156
PDF
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial
2021
·
Neil Formica
, Raburn Mallory
, et al.
·
PLoS Medicine
·
111
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
2022
·
Raburn M Mallory
, Neil Formica
, et al.
·
The Lancet Infectious Diseases
·
101
Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia
2008
·
Anthony T. Newall
, Julia M. L. Brotherton
, et al.
·
Clinical Infectious Diseases
·
91
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children
2008
·
Terry Nolan
, Peter C. Richmond
, et al.
·
Vaccine
·
89
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
2008
·
Terry M. Nolan
, Peter C. Richmond
, et al.
·
Vaccine
·
78
The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease
2001
·
N. FORMICA
, M. YATES
, et al.
·
Epidemiology and Infection
·
57
PDF
Abattoir‐associated Q fever: a Q fever outbreak during a Q fever vaccination program
2001
·
Nicole Gilroy
, Neil Formica
, et al.
·
Australian and New Zealand Journal of Public Health
·
47
PDF
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study
2017
·
John T. Treanor
, Frank R. Albano
, et al.
·
Vaccine
·
35
PDF
Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
2008
·
H. Keipp Talbot
, Wendy Keitel
, et al.
·
Vaccine
·
35
Legionnaires' disease outbreak: Victoria's largest identified outbreak
2000
·
Neil Formica
, Graham Tallis
, et al.
·
Communicable Diseases Intelligence
·
20
Place of bupropion in smoking-cessation therapy
2001
·
Chris Silagy
, Neil Formica
·
The Lancet
·
16
Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study
2017
·
Jolanta Airey
, Frank R. Albano
, et al.
·
Vaccine
·
9
PDF
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination
2023
·
Louis Fries
, Neil Formica
, et al.
·
The Journal of Infectious Diseases
·
6
Randomized Study to Compare Immunogenicity and Safety of Seqirus* Quadrivalent Inactivated Influenza Vaccine With a US-Registered Influenza Vaccine in Pediatric Subjects Aged 5 to 17 Years
2016
·
Jane Leong
, Daphne Sawlwin
, et al.
·
Open Forum Infectious Diseases
PDF
Show more works
View as search
Works count:
16
Citation count:
1,851
H-index:
12
I10-index:
12
Year
Topic
Type
